Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

989
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
989
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

1.7K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
1.7K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

1.3K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
1.3K
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

1.7K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
1.7K
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

1.1K
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Controlled self-assembly of a pyrene-based bolaamphiphile by acetate ions: from nanodisks to nanofibers by fluorescence enhancement.

Soft matter·2015
Same author

Gradual-order enhanced stability: a frozen section of electrospun nanofibers for energy storage.

Nanoscale·2015
Same author

[Association of human epicardial adipose tissue volume and inflammatory mediators with atherosclerosis and vulnerable coronary atherosclerotic plaque].

Zhonghua xin xue guan bing za zhi·2015
Same author

Ultrasensitive SERS detection of trinitrotoluene through capillarity-constructed reversible hot spots based on ZnO-Ag nanorod hybrids.

Nanoscale·2015
Same author

pERK1/2 silencing sensitizes pancreatic cancer BXPC-3 cell to gemcitabine-induced apoptosis via regulating Bax and Bcl-2 expression.

World journal of surgical oncology·2015
Same author

Probing and controlling liquid crystal helical nanofilaments.

Nano letters·2015

Related Experiment Video

Updated: Jul 27, 2025

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.2K

Myeloid/lymphoid neoplasm with

Dong Chen1, Guang Liu2, Michael R Lewis3

  • 1Pathology and Laboratory Medicine, University of Connecticut, Farmington, CT, United States.

Leukemia Research Reports
|June 5, 2023
PubMed
Summary

This study details the first reported case of myeloid/lymphoid neoplasm with ZMYM2::FGFR1 rearrangement showing complex evolution. The cancer transformed through T-lymphoblastic lymphoma, myeloproliferative neoplasm, systemic mastocytosis, and acute myeloid leukemia stages.

Keywords:
Acute myeloid leukemiaMyeloid/lymphoid neoplasm with FGFR1 rearrangement (MLNFGFR1)Systemic mastocytosisT-lymphoblastic lymphomaZMYM2::FGFR1

More Related Videos

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

11.7K
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.0K

Related Experiment Videos

Last Updated: Jul 27, 2025

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.2K
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

11.7K
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.0K

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Myeloid/lymphoid neoplasms represent a heterogeneous group of cancers.
  • ZMYM2::FGFR1 rearrangements are associated with specific hematologic malignancies.

Observation:

  • A unique case of myeloid/lymphoid neoplasm with ZMYM2::FGFR1 rearrangement was observed.
  • The neoplasm exhibited a complex, multi-stage disease progression.

Findings:

  • The initial presentation involved T-lymphoblastic lymphoma and myeloproliferative neoplasm with eosinophilia.
  • The disease evolved to systemic mastocytosis and subsequently transformed into acute myeloid leukemia.
  • Secondary genetic abnormalities including JAK3 mutations, chromosome 21 gain, and RUNX1 mutations were identified during the evolution.

Implications:

  • This case highlights the potential for complex trilineage and phenotypic evolution in myeloid/lymphoid neoplasms.
  • Understanding these complex transformations is crucial for accurate diagnosis and treatment strategies.
  • Further research into ZMYM2::FGFR1-associated neoplasms may reveal novel therapeutic targets.